X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Divis Laboratories with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs TEVA PHARMA (Israel) - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DIVIS LABORATORIES   TEVA PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
TEVA PHARMA
Dec-13
DIVIS LABORATORIES/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2222,709-   
Low Rs7842,353-   
Sales per share (Unadj.) Rs153.11,554.5-  
Earnings per share (Unadj.) Rs39.997.1-  
Cash flow per share (Unadj.) Rs44.6222.8-  
Dividends per share (Unadj.) Rs10.0085.01-  
Dividend yield (eoy) %1.03.4 29.7%  
Book value per share (Unadj.) Rs201.81,726.7-  
Shares outstanding (eoy) m265.47848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.61.6 402.4%   
Avg P/E ratio x25.126.1 96.3%  
P/CF ratio (eoy) x22.511.4 198.0%  
Price / Book Value ratio x5.01.5 339.1%  
Dividend payout %25.087.5 28.6%   
Avg Mkt Cap Rs m266,2662,146,042 12.4%   
No. of employees `0009.744.9 21.7%   
Total wages/salary Rs m4,6870-   
Avg. sales/employee Rs Th4,175.029,328.6 14.2%   
Avg. wages/employee Rs Th481.50-   
Avg. net profit/employee Rs Th1,089.31,832.1 59.5%   
INCOME DATA
Net Sales Rs m40,6431,318,175 3.1%  
Other income Rs m7490-   
Total revenues Rs m41,3921,318,175 3.1%   
Gross profit Rs m14,460360,983 4.0%  
Depreciation Rs m1,233106,549 1.2%   
Interest Rs m2325,891 0.1%   
Profit before tax Rs m13,953228,543 6.1%   
Minority Interest Rs m01,038 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-150,026 0.0%   
Tax Rs m3,349-2,790 -120.0%   
Profit after tax Rs m10,60482,345 12.9%  
Gross profit margin %35.627.4 129.9%  
Effective tax rate %24.0-1.2 -1,966.0%   
Net profit margin %26.16.2 417.7%  
BALANCE SHEET DATA
Current assets Rs m40,105890,291 4.5%   
Current liabilities Rs m6,595776,409 0.8%   
Net working cap to sales %82.58.6 954.4%  
Current ratio x6.11.1 530.4%  
Inventory Days Days11991 130.6%  
Debtors Days Days8196 84.1%  
Net fixed assets Rs m19,995430,545 4.6%   
Share capital Rs m5313,245 16.4%   
"Free" reserves Rs m53,0430-   
Net worth Rs m53,5741,464,243 3.7%   
Long term debt Rs m0674,012 0.0%   
Total assets Rs m61,5853,012,453 2.0%  
Interest coverage x618.49.8 6,292.9%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.70.4 150.8%   
Return on assets %17.33.6 480.3%  
Return on equity %19.85.6 352.0%  
Return on capital %26.14.9 529.0%  
Exports to sales %00-   
Imports to sales %25.20-   
Net fx Rs m24,9850-   
CASH FLOW
From Operations Rs m11,493210,049 5.5%  
From Investments Rs m-11,372-74,429 15.3%  
From Financial Activity Rs m-93-251,968 0.0%  
Net Cashflow Rs m28-116,348 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare DIVIS LABORATORIES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare DIVIS LABORATORIES With: ELDER PHARMA  ALEMBIC LTD  UNICHEM LAB  CADILA HEALTHCARE  SANOFI INDIA  



Today's Market

Sensex Continues Momentum; Metal Sector Up 2.5%(11:30 am)

After opening the day on a positive note, stock markets in India have continued their momentum. Sectoral indices are trading on a positive note with stocks in the metal sector.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 23, 2018 12:49 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS